Alexion Pharmaceuticals (ALXN) Shares Gap Up on Analyst Upgrade

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) gapped up before the market opened on Tuesday after Stifel Nicolaus raised their price target on the stock from $130.00 to $136.00. The stock had previously closed at $127.35, but opened at $128.69. Stifel Nicolaus currently has a hold rating on the stock. Alexion Pharmaceuticals shares last traded at $128.94, with a volume of 50491 shares changing hands.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $152.00 price objective for the company in a report on Monday, July 16th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 10th. Robert W. Baird set a $165.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday. Citigroup lifted their price objective on shares of Alexion Pharmaceuticals from $173.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday. Finally, ValuEngine upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 12th. Two analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $159.50.

In other Alexion Pharmaceuticals news, CFO Paul J. Clancy sold 5,241 shares of the firm’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $131.11, for a total transaction of $687,147.51. Following the transaction, the chief financial officer now owns 93,309 shares of the company’s stock, valued at approximately $12,233,742.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.35% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXN. Point72 Asia Hong Kong Ltd increased its position in Alexion Pharmaceuticals by 3,156.7% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 947 shares during the period. Advisory Services Network LLC increased its position in Alexion Pharmaceuticals by 145.3% during the 2nd quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 523 shares during the period. Berson & Corrado Investment Advisors LLC purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $205,000. Financial Gravity Wealth Inc. purchased a new position in shares of Alexion Pharmaceuticals in the 1st quarter worth approximately $211,000. Finally, Essex Financial Services Inc. purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter worth approximately $232,000. 93.02% of the stock is currently owned by institutional investors and hedge funds.

The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72. The stock has a market capitalization of $28.64 billion, a PE ratio of 26.02, a P/E/G ratio of 1.24 and a beta of 0.84.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.58. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $976.81 million. During the same quarter in the previous year, the firm earned $1.56 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. analysts predict that Alexion Pharmaceuticals, Inc. will post 6.45 earnings per share for the current year.

Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Further Reading: How to Use a Moving Average for Trading 

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply